<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 01 Jun 2021 18:02:35 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>ASCO 2021 | 高光时刻！恒瑞医药“双艾组合”多项研究进展将重磅公布</title><link>https://mp.weixin.qq.com/s/5AKHUDavZd4kBVqzFuXzag</link><description></description><content:encoded><![CDATA[ASCO 2021 | 高光时刻！恒瑞医药“双艾组合”多项研究进展将重磅公布]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:54:44 +0800</pubDate></item><item><title>创新医疗支付模式，提高罕见病新药可及性！神州细胞与镁信健康达成战略合作</title><link>https://mp.weixin.qq.com/s/6fJPiL05-pxKEIgjrfrA8g</link><description></description><content:encoded><![CDATA[创新医疗支付模式，提高罕见病新药可及性！神州细胞与镁信健康达成战略合作]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:54:44 +0800</pubDate></item><item><title>万春医药提交普那布林美国上市申请，获FDA优先审评</title><link>https://mp.weixin.qq.com/s/caO-vUtLMs-b4TriNQIFcg</link><description></description><content:encoded><![CDATA[万春医药提交普那布林美国上市申请，获FDA优先审评]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:54:44 +0800</pubDate></item><item><title>1.89亿美元！信达生物引进ROS1/NTRK抑制剂</title><link>https://mp.weixin.qq.com/s/lhWtmAMA8ix1N18Xu7xnGA</link><description></description><content:encoded><![CDATA[1.89亿美元！信达生物引进ROS1/NTRK抑制剂]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:54:44 +0800</pubDate></item><item><title>口服CGRPR拮抗剂新适应症获批，预防偏头痛发作</title><link>https://mp.weixin.qq.com/s/h0qabd14pAQ2Pkng0K0Wyw</link><description></description><content:encoded><![CDATA[口服CGRPR拮抗剂新适应症获批，预防偏头痛发作]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:54:44 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 南京站</title><link>https://mp.weixin.qq.com/s/9UoKPwo5oH3OUrNncRV0yw</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 南京站]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:54:44 +0800</pubDate></item><item><title>首个国产一线肝细胞癌靶向药物即将获批上市</title><link>https://mp.weixin.qq.com/s/EG9jvFGxUmSsg84GKVVVYg</link><description></description><content:encoded><![CDATA[首个国产一线肝细胞癌靶向药物即将获批上市]]></content:encoded><pubDate>Mon, 31 May 2021 11:27:07 +0800</pubDate></item><item><title>信达生物信迪利单抗第3项适应症即将获批，一线治疗鳞状NSCLC</title><link>https://mp.weixin.qq.com/s/IWgwwoZD8UB_f8WUtJ_Cuw</link><description></description><content:encoded><![CDATA[信达生物信迪利单抗第3项适应症即将获批，一线治疗鳞状NSCLC]]></content:encoded><pubDate>Mon, 31 May 2021 11:27:07 +0800</pubDate></item><item><title>第2家！豪森药业「厄洛替尼片」通过一致性评价</title><link>https://mp.weixin.qq.com/s/irvILv2BqBUM5agyNGRMrQ</link><description></description><content:encoded><![CDATA[第2家！豪森药业「厄洛替尼片」通过一致性评价]]></content:encoded><pubDate>Mon, 31 May 2021 11:27:07 +0800</pubDate></item><item><title>扬子江1类新药「注射用磷酸左奥硝唑酯二钠」获批上市</title><link>https://mp.weixin.qq.com/s/9ffqRUEwBroCZE7XY2NFxg</link><description></description><content:encoded><![CDATA[扬子江1类新药「注射用磷酸左奥硝唑酯二钠」获批上市]]></content:encoded><pubDate>Mon, 31 May 2021 11:27:07 +0800</pubDate></item><item><title>第五批国采品种5月过评情况汇总（附完整清单下载）</title><link>https://mp.weixin.qq.com/s/RbikmjNPSfRFJ8P0uW4XAQ</link><description></description><content:encoded><![CDATA[第五批国采品种5月过评情况汇总（附完整清单下载）]]></content:encoded><pubDate>Sun, 30 May 2021 19:21:57 +0800</pubDate></item><item><title>第四批国采，全国31省市已全部落地执行</title><link>https://mp.weixin.qq.com/s/4KWIGFP0WmVcUGRmFYflfQ</link><description></description><content:encoded><![CDATA[第四批国采，全国31省市已全部落地执行]]></content:encoded><pubDate>Sun, 30 May 2021 19:21:57 +0800</pubDate></item><item><title>重磅！安进AMG 510获FDA加速批准上市</title><link>https://mp.weixin.qq.com/s/65qTCDKQJtUjFCxXkR9HvQ</link><description></description><content:encoded><![CDATA[重磅！安进AMG 510获FDA加速批准上市]]></content:encoded><pubDate>Sat, 29 May 2021 02:53:00 +0800</pubDate></item><item><title>直播预告 | 各家药品专利期限补偿谁更赚？专利法第四次修改对国内上市药品的影响</title><link>https://mp.weixin.qq.com/s/ME5_-uVZ652GJAsv5nocfQ</link><description></description><content:encoded><![CDATA[直播预告 | 各家药品专利期限补偿谁更赚？专利法第四次修改对国内上市药品的影响]]></content:encoded><pubDate>Sat, 29 May 2021 02:53:00 +0800</pubDate></item><item><title>肿瘤浸润淋巴细胞疗法BLA再遭延迟，CEO离职，公司股价暴跌</title><link>https://mp.weixin.qq.com/s/6mhjx2KQ5Cz4zyZEA59VZQ</link><description></description><content:encoded><![CDATA[肿瘤浸润淋巴细胞疗法BLA再遭延迟，CEO离职，公司股价暴跌]]></content:encoded><pubDate>Fri, 28 May 2021 18:20:56 +0800</pubDate></item><item><title>百时美施贵宝 S1PR1/5 调节剂新适应症获FDA批准，治疗溃疡性结肠炎</title><link>https://mp.weixin.qq.com/s/SPjaxkLsDNMBKK4eSqF8SA</link><description></description><content:encoded><![CDATA[百时美施贵宝 S1PR1/5 调节剂新适应症获FDA批准，治疗溃疡性结肠炎]]></content:encoded><pubDate>Fri, 28 May 2021 18:20:56 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 南京站</title><link>https://mp.weixin.qq.com/s/njLg_5oVak3qAc7HFKprJQ</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 南京站]]></content:encoded><pubDate>Fri, 28 May 2021 18:20:56 +0800</pubDate></item><item><title>基石药业PD-L1治疗III期NSCLC注册性临床试验成功，拟递交新药上市申请</title><link>https://mp.weixin.qq.com/s/J28c8cxEEj30z3htYdGlIA</link><description></description><content:encoded><![CDATA[基石药业PD-L1治疗III期NSCLC注册性临床试验成功，拟递交新药上市申请]]></content:encoded><pubDate>Fri, 28 May 2021 18:20:56 +0800</pubDate></item><item><title>贝达药业「埃克替尼片」新适应症即将获批，NSCLC术后辅助治疗</title><link>https://mp.weixin.qq.com/s/W1gGcRtLAc4vGfQQQiDAEA</link><description></description><content:encoded><![CDATA[贝达药业「埃克替尼片」新适应症即将获批，NSCLC术后辅助治疗]]></content:encoded><pubDate>Fri, 28 May 2021 18:20:56 +0800</pubDate></item><item><title>扬子江1类新药「注射用磷酸左奥硝唑酯二钠」即将获批</title><link>https://mp.weixin.qq.com/s/54gvl1TN4FyEXZcc3PFAmg</link><description></description><content:encoded><![CDATA[扬子江1类新药「注射用磷酸左奥硝唑酯二钠」即将获批]]></content:encoded><pubDate>Fri, 28 May 2021 18:20:56 +0800</pubDate></item></channel></rss>